13F Pro13F Pro

GREAT POINT PARTNERS LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1281446
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare97.5%$413.7M
  • Financials2.5%$10.8M

AUM History

13fpro.ai/research/fund/great-point-partners-llc-1281446

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/great-point-partners-llc-1281446

GREAT POINT PARTNERS LLC 13F holdings — Q2 2026

$529.1M portfolio (+21.6% QoQ) · 42 holdings · Q2 2026 13F · top 10 are 54% of the stock portfolio

Includes $104.7M of put/call options ($46.3M puts, $58.4M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $424.4M. Weights use the stock portfolio.

All holdings — GREAT POINT PARTNERS LLC (Q2 2026)

42 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ABVX$ABVXCALLAbivax S.A.$53.3MNew
IBRX$IBRXPUTImmunityBio, Inc.$26.3M—
RARE$RAREPUTUltragenyx Pharmaceutical Inc.$20.0MNew
SGMT$SGMTSagimet Biosciences Inc.$15.7MNew
CTNM$CTNMContineum Therapeutics, Inc.$15.1M+15%
IMMX$IMMXImmix Biopharma, Inc.$13.2M+265%
CLYM$CLYMClimb Bio, Inc.$13.0M-25%
AMLX$AMLXAmylyx Pharmaceuticals, Inc.$12.6M-60%
NKTR$NKTRNEKTAR THERAPEUTICS$12.2M-45%
NGNE$NGNENeurogene Inc.$11.1M-30%
LBRX$LBRXLB PHARMACEUTICALS INC$10.3M+6%
IRD$IRDOpus Genetics, Inc.$8.1M+507%
EPRX$EPRXEUPRAXIA PHARMACEUTICALS INC.$7.9M—
DRUG$DRUGBRIGHT MINDS BIOSCIENCES INC.$7.7M-50%
IFRX$IFRXInflaRx N.V.$6.8MNew

What changed in Q2 2026

Against the previous quarter's 13F: 12 new, 7 added to, 10 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.

New positions (12)

  • ABVX$ABVXCALLAbivax S.A.$53.3M

    first bought this quarter

  • ABVX$ABVXAbivax S.A.$27.2M

    first bought this quarter

  • RARE$RAREPUTUltragenyx Pharmaceutical Inc.$20.0M

    first bought this quarter

  • DFTX$DFTXDefinium Therapeutics, Inc.$20.0M

    first bought this quarter

  • SGMT$SGMTSagimet Biosciences Inc.$15.7M

    first bought this quarter

  • IFRX$IFRXInflaRx N.V.$6.8M

    first bought this quarter

+6 more in the Excel export

Added to (7)

  • VERA$VERAVera Therapeutics, Inc.+201%

    now $25.8M · held 2 qtrs, 2 adds in a row

  • IMMX$IMMXImmix Biopharma, Inc.+265%

    now $13.2M · held 2 qtrs, 2 adds in a row

  • MLTX$MLTXMoonLake Immunotherapeutics+71%

    now $16.7M · held 2 qtrs, 2 adds in a row

  • IRD$IRDOpus Genetics, Inc.+507%

    now $8.1M · held 2 qtrs, 2 adds in a row

  • ANNX$ANNXAnnexon, Inc.+40%

    now $20.0M · held 2 qtrs, 2 adds in a row

  • CTNM$CTNMContineum Therapeutics, Inc.+15%

    now $15.1M · held 3 qtrs

+1 more in the Excel export

Trimmed (10)

  • SCYX$SCYXSCYNEXIS INC-88%

    now $3.8M · held 2 qtrs

  • AMLX$AMLXAmylyx Pharmaceuticals, Inc.-60%

    now $12.6M · held 6 qtrs

  • NKTR$NKTRNEKTAR THERAPEUTICS-45%

    now $12.2M · held 4 qtrs

  • DRUG$DRUGBRIGHT MINDS BIOSCIENCES INC.-50%

    now $7.7M · held 2 qtrs

  • SLN$SLNSilence Therapeutics plc-56%

    now $4.9M · held 3 qtrs

  • NGNE$NGNENeurogene Inc.-30%

    now $11.1M · held 10+ qtrs

+4 more in the Excel export

Sold out (12)

  • APGE$APGEApogee Therapeutics, Inc.was $31.5M

    held 3 qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $13.6M

    held 2 qtrs

  • IMVT$IMVTImmunovant, Inc.was $13.6M

    held 5 qtrs

  • JBIO$JBIOJade Biosciences, Inc.was $13.6M

    held 4 qtrs

  • ZBIO$ZBIOZenas BioPharma, Inc.was $10.2M

    held 1 qtr

  • CMPX$CMPXCompass Therapeutics, Inc.was $7.1M

+6 more in the Excel export

Firm AUM (Form ADV): $1.8B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F GREAT POINT PARTNERS LLC has filed, 41 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow GREAT POINT PARTNERS?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.

Average quality of GREAT POINT PARTNERS's top 20 holdings: 12/100 (our AI quality score, weighted by position size; 4 of the 20 are scored)

Top 10 since filing

-24.7%

Value-weighted move of the 10 largest stock positions

Turnover

34%

Last quarter; 146% over the last 4

Top 10 weight

54%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

22%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 7 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

GREAT POINT PARTNERS LLC disclosed 42 positions worth $529.1M in its Form 13F-HR for Q2 2026 — $424.4M in common stock plus $104.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $VOR (Vor Biopharma Inc.) at 7.4% of the equity portfolio, followed by $ABVX and $VERA. During the quarter the fund opened 12 new positions and exited 12 — including a new stake in $ABVX and a full exit from $APGE. The portfolio is most concentrated in Healthcare (97.5% of disclosed assets). All figures are sourced directly from GREAT POINT PARTNERS LLC’s Form 13F-HR filing with the SEC under CIK 1281446.

Funds like this

managers whose biggest positions overlap GREAT POINT PARTNERS's
TCG Crossover Management, LLC$4.16B 13F book · 7 shared top holdingsABVXAMLXVORLBRXIkarian Capital, LLC$928.17M 13F book · 8 shared top holdingsABVXALMSVERACTNMCormorant Asset Management, LP$1.95B 13F book · 8 shared top holdingsALMSABVXMLTXORKAOctagon Capital Advisors LP$1.11B 13F book · 5 shared top holdingsABVXALMSDFTXPALIDeep Track Capital, LP$6.87B 13F book · 7 shared top holdingsORKAALMSVERAMLTXSaturn V Capital Management LP$697.47M 13F book · 6 shared top holdingsABVXALMSIMMXAMLX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: GREAT POINT PARTNERS LLC

13F Pro is an AI hedge fund tracker and stock research platform. For GREAT POINT PARTNERS LLC (SEC CIK: 1281446), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in GREAT POINT PARTNERS LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.